Pasithea Therapeutics Corp. Common Stock (KTTA) Stock Price

KTTAStock

$0.56−29.58%52W

Market Cap$18.71M

P/E—

PEG Ratio—

Div yield—

Beta0.28

KTTA Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-39.12%

Price vs S&P 500 (4W)9.17%

VGM Score67.49

Book Value / Share (Quarterly)$2.20

P/TBV (Annual)0.53x

Indicated Dividend (Annual)$0.00

Cash Flow / Share (Quarterly)$-0.56

Price vs S&P 500 (YTD)-72.81%

Gross Margin (TTM)100.54%

Net Profit Margin (TTM)-6478.41%

EPS (TTM)$-1.98

10-Day Avg Trading Volume0.14M

EPS Excl Extra (TTM)$-1.98

EPS (Annual)$-13.01

ROI (Annual)-68.22%

Gross Margin (Annual)-14.57%

Cash / Share (Quarterly)$2.02

ROA (Last FY)-61.12%

Revenue Growth TTM (YoY)740.47%

EBITD / Share (TTM)$-1.76

Operating Margin (TTM)-7032.69%

Cash Flow / Share (Annual)$-9.99

P/B Ratio0.29x

P/B Ratio (Quarterly)0.34x

Net Income / Employee (Annual)$-3,192,300

Net Interest Coverage (TTM)-4346.00x

ROA (TTM)-53.61%

EPS Incl Extra (Annual)$-13.01

Current Ratio (Annual)6.58x

Quick Ratio (Quarterly)34.17x

3-Month Avg Trading Volume0.65M

52-Week Price Return-29.58%

Revenue / Employee (TTM)$16,047,330,000

Tangible BV / Share (Quarterly)$2.05

P/S Ratio (Annual)1057.76x

Asset Turnover (Annual)0.00x

52-Week High$2.06

EPS Excl Extra (Annual)$-13.01

26-Week Price Return-27.88%

Quick Ratio (Annual)6.31x

13-Week Price Return-29.96%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)35.40x

Enterprise Value$-34.43M

Asset Turnover (TTM)0.01x

Revenue / Employee (Annual)$3,000

Pretax Margin (Annual)-14394.04%

Cash / Share (Annual)$4.97

3-Month Return Std Dev70.63%

Net Income / Employee (TTM)$-3,946,800

ROE (Last FY)-68.22%

Net Interest Coverage (Annual)-121163.20x

EPS Basic Excl Extra (Annual)$-13.01

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-1.98

ROI (TTM)-57.44%

P/S Ratio (TTM)26.84x

Revenue / Share (Annual)$0.01

Tangible BV / Share (Annual)$5.36

Price vs S&P 500 (52W)-47.89%

Year-to-Date Return-60.85%

5-Day Price Return1.49%

EPS Normalized (Annual)$-13.01

Net Profit Margin (Annual)-14394.04%

Month-to-Date Return9.81%

Cash Flow / Share (TTM)$-0.60

EBITD / Share (Annual)$-13.01

Operating Margin (Annual)-29850.33%

EPS Basic Excl Extra (TTM)$-1.98

P/TBV (Quarterly)0.36x

P/B Ratio (Annual)0.27x

Pretax Margin (TTM)-6478.41%

Book Value / Share (Annual)$10.60

Price vs S&P 500 (13W)-32.75%

Beta0.28x

Revenue / Share (TTM)$0.01

ROE (TTM)-57.44%

52-Week Low$0.28

gGradeA

mGradeC

vgmGradeB

KTTA Earnings Surprise History

Q3 25-0.41est. —

Q4 25-0.89est. -0.18

Q1 26-0.12est. -0.45

Q2 26-0.16est. -0.16

KTTA Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.14

Industry Peers — Pharmaceuticals(571)

Symbol	Value Score	Growth Score	Momentum Score	Price
KTTAPasithea Therapeutics Corp. Common Stock	—	A	C	$0.56
LLYEli Lilly & Co.	D	B	B	$1233.66
JNJJohnson & Johnson	D	C	B	$273.14
ABBVABBVIE INC.	D	C	B	$265.79
MRKMerck & Co., Inc.	D	C	A	$156.45
NVSNovartis AG	C	C	C	$159.98
AZNAstraZeneca PLC	C	B	C	$169.66
NVONovo-Nordisk A/S	B	C	C	$48.66
ABTAbbott Laboratories	C	C	B	$116.13
PFEPfizer Inc.	C	D	C	$28.57
VRTXVertex Pharmaceuticals Inc	D	C	B	$552.85
BMYBristol-Myers Squibb Co.	B	B	B	$67.92
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	C	C	$46.02
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	B	C	C	$52.07
REGNRegeneron Pharmaceuticals Inc	C	C	B	$833.56
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	C	$18.35
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$38.10
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	C	$376.37
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	B	$62.07
ALNYAlnylam Pharmaceuticals, Inc.	D	A	D	$240.08
ZTSZOETIS INC.	B	C	D	$77.29
INSMInsmed, Inc.	F	A	C	$123.89
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	$36.47
UTHRUnited Therapeutics Corp	C	C	C	$518.53
GMABGenmab A/S ADS	C	C	B	$34.36
VTRSViatris Inc. Common Stock	B	C	B	$16.72
JAZZJazz Pharmaceuticals, Inc.	B	C	B	$260.23
ASNDAscendis Pharma A/S Ordinary Share	D	A	C	$252.99
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	$80.40
CORTCorcept Therapeutics Inc.	F	C	A	$123.57
BMRNBioMarin Pharmaceuticals Inc	C	C	C	$66.12
ARWRArrowhead Research Corporation	D	A	B	$88.88
ELANElanco Animal Health Incorporated Common Stock	C	B	B	$25.09
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	$512.16
CYTKCytokinetics Inc.	F	D	B	$77.46
AXSMAxsome Therapeutics, Inc	D	B	C	$205.48
SMMTSummit Therapeutics Inc. Common Stock	F	—	D	$13.36
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	$63.57
ABVXAbivax SA American Depositary Shares	—	—	C	$117.93
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	D	C	$12.34
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	$368.02
NUVLNuvalent, Inc. Class A Common Stock	—	—	B	$123.96
PTGXProtagonist Therapeutics, Inc	F	B	A	$150.59
SYRESpyre Therapeutics, Inc. Common Stock	—	—	A	$107.36
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	$84.86
TGTXTG Therapeutics, Inc.	D	B	A	$55.42
ALKSAlkermes Inc. plc	D	C	B	$49.21
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	$113.35
ORKAOruka Therapeutics, Inc. Common Stock	F	—	A	$101.82
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	$161.68
COGTCogent Biosciences, Inc. Common Stock	F	—	B	$36.80

About Pasithea Therapeutics Corp. Common Stock

Pasithea Therapeutics is a biotechnology company developing treatments for central nervous system disorders and genetic diseases, including neurofibromatosis type 1, amyotrophic lateral sclerosis, multiple sclerosis, schizophrenia, and RASopathies. Its pipeline includes PAS-004, a MEK1/2 inhibitor; PAS-003, a monoclonal antibody; and PAS-001, a small molecule therapeutic. The company leverages expertise in neuroscience and translational medicine to address significant unmet medical needs.